Background: Aspirin and other NSAIDs are widely used as analgesics and the former is a preventative agent for vascular events. It is unclear whether their longterm use affects cancer risk. Data on the chemopreventative role of these drugs on the mortality in patients with upper aerodigestive tract cancer (UADT) are insufficient.
Introduction
Cancer of the upper aerodigestive tract (UADT) (oral cavity, pharynx, larynx and oesophagus combined) is, globally, the fourth most common cancer and cause of cancer mortality, with over million incident cases and over 700,000 deaths worldwide [1] . While a decrease in mortality was noted in the European Union (EU) overall between 1993 and 2004, a persistent rise was observed in central and eastern European countries [2] . European mean age-standardised 5-year relative survival was 39.9% for Head and Neck Cancer (HNC) and 12.4% for cancer of the oesophagus [3] .
Prophylactic aspirin has been considered to be beneficial in reducing the risks of heart disease and cancer. Previous research showed the decreased risk of cancer of the UADT associated with the use of non-COX-2 inhibitors, NSAIDs and long-term aspirin therapy [4, 5] . Analysis of individual patient data from randomised clinical trials of daily aspirin [7] showed a significant reduction in death due to cancer, however there were no data reported in this study on HNC. Observational study by Rachidi et al [6] showed that post-diagnosis treatment of patients with head and neck squamous cell carcinoma with antiplatelet medications (including aspirin and other NSAIDs) was associated with better prognosis.
The aim of this study was to investigate the effect of aspirin and other NSAIDs use on the risk of UADT cancers. Specific objectives were to investigate risk by cancer subsite, duration of use and type of NSAIDs.
Material and Methods
An observational cohort study of patients with UADT cancer was undertaken using Primary Care Clinical Informatics Unit (PCCIU) database of electronic medical records in Scotland (http://www.abdn.ac.uk/pcciu/). PCCIU Research database includes data from more than 200 participating medical practices and approximately one million patients. Data reflect the computerized clinical record, including appointments, repeat and acute prescribing, call/recall, and screening. Ethical permission was not required as the data were anonymised and individuals could not be identified.
Patients with first time UADT cancer (oral cavity, oropharynx, hypopharynx, larynx and oesophagus) diagnosed in 1996 or later were identified using READ codes (http://systems.hscic.gov.uk/data/uktc/readcodes) as described in Table 1 . Carcinoma in situ and patients aged <18 years at diagnosis were excluded. We used all the available eligible patients in the PCCIU database. Participants with cancer diagnosis before diagnosis with UADT cancer were excluded (READ codes B0%, B1%, B2%, B3%, B4%, B5%, B6%, B9%, BA%, BB%, By%).
Participants entered the study on the date of UADT cancer diagnosis and exited the study on the date of last appointment at their medical practice, date of deregistration with the practice or date of death. There was no information on cause of death.
To measure exposure, we identified prescriptions of oral aspirin, Cyclooxygenase 2 Inhibitors (COX-2) or other NSAIDs. Additional data in the database were available on patients' age at diagnosis, gender, practice deprivation (Carstairs index) [8] , selfreported smoking status before diagnosis (never/ever) and most recent alcohol consumption (high consumption was defined as above the recommended limit of 2-3 units a day for women and 3-4 units a day for men). Information was also obtained on history of coronary heart disease (CHD), atrial fibrillation (AF) and stroke. Hazard Ratios (HRs) with 95% confidence intervals (CIs) adjusted for the potential confounding factors (age, gender, deprivation, smoking and alcohol consumption) were estimated using Cox regression model. Proportional hazards assumption was tested using stphtest and stphplot procedures in STATA. Continuous variables were categorised using median or tertiles of the overall distribution as appropriate. Age was a priori categorised as following: 18-55, 56-65, 66-75 and 76-99 years. Multiple imputation with ten imputed datasets was performed using mi procedure in STATA for smoking and alcohol consumption with all variables used in the analysis included in the imputation [9] .
Additional analysis was conducted using nested case-control design. Those who had died were considered cases. These were matched on gender, age (within 5-years) and year of cancer diagnosis (within 2-years) separately for each site to one control who lived at least as long after diagnosis as the matched case. Conditional logistic regression was used to estimate Odds Ratios (ORs) with 95% CI adjusted for the potential confounding factors.
Results
We identified 2,392 patients with UADT cancer (1, 195 Older age, male gender, deprivation, smoking, high (above the recommended limit) alcohol consumption, AF and stroke associated with poor survival in HNC patients.
Among patients with oesophageal cancer, poor survival was associated with older age, male gender, smoking, CHD, AF, stroke and aspirin prescription before diagnosis (Table 2 ). For both cancer sites, 'later entry to the cohort was associated with shorter survival: HR 2.01 (95% CI 1.56, 2.60) in HNC patients and HR 1.64 (95% CI 1.36, 
Discussion
This first large Scotland-based general practice-derived study of survival showed a decrease in risk of UADT cancer with aspirin prescriptions irrespective of timing after diagnosis or volume.
Other studies of cancer patients showed improved survival among those taking aspirin. In meta-analysis of eight trials (25 570 patients, 674 cancer deaths), allocation to aspirin reduced death due to cancer (pooled Odds Ratio (OR) 0.79, 95% CI 0.68-0.92) [7] . In further analysis of individual patient data from seven randomised trials of daily aspirin versus no aspirin, there were no data reported specifically on head and neck cancer, but there was a non-significant decrease in risk of death due to oesophageal cancer (HR 0.78 95% CI 0.27, 2.23 for 0-5 years of follow up and HR 0.43 95% CI 0.11, 1.72 for 5 years follow up or longer) [7] .
Study of aspirin use and survival after diagnosis of breast cancer showed a reduction in both all-cause (HR 0.53, 95% CI 0.45, 0.63) and breast-cancer specific mortality (HR 0.42, 95% CI 0.31, 0.55) [10] . In a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial, aspirin use and COX-2 inhibitors use were associated with improved overall survival (HR 0.63, 95% CI 0.35 to 1.12) and 0.50 (95% CI 0.23 to 1.07), respectively [11] . Study of treatment with antiplatelet medications (including aspirin and other NSAIDs) after diagnosis with head and neck squamous cell carcinoma was associated with longer overall survival [HR 0.76, 95% CI 0.58-0.99] [6] .
The chemopreventive effect of aspirin and other NSAIDs has been partially attributed to their inhibition of the cyclo-oxygenase (COX) enzymes and reduced production of prostaglandins and other inflammatory mediators [7] . Platelets play a multifaceted and important role in cancer biology [12] and therefore development of platelet inhibitors that influence malignancy progression and study of currently available antiplatelet drugs represents a promising area of targeted cancer therapy [12 , 6] .
IEW ARTICLE
The strength of this study is that as results are likely to be representative of the general population because the majority of the UK population is registered with a general medical practice.
However the study has several methodological deficiencies. The study had a limited sample size particularly for investigation of prescription density and prescription timing. No information was available regarding the histological sub-type, cancer stage or treatment. We could only investigate all-cause mortality as there was no information on cause of death. Study by Ning et al [13] reported that while cancer is the major cause of death among cancer patients, approximately half of participants died from other diseases and complications, such as cardiovascular and respiratory diseases. The authors concluded that clinicians and cancer survivors should pay attention to the prevention and treatment of other diseases and complications.
For both cancer sites, 'later entry to the cohort was associated with shorter survival.
These results may reflect differences in diagnostic tools, changes in clinical guidelines over time or some other residual confounding.
NSAID exposure was measured in terms of prescriptions issued and we did not have reliable information on dose or indication for use of aspirin or other NSAIDs. However Rothwell et al [7] reported that benefit of taking aspirin on cancer death was unrelated to aspirin dose (75 mg upwards). While low dose aspirin is mostly prescribed for prevention of cardiovascular events, other NSAIDs may be prescribed for cancer pain [14, 15] . The issue of a prescription does not mean that the medicine was actually used. A questionnaire-based study conducted in UK general medical practices which compared prescribed NSAIDs and described by patients reported mean (SD) compliance (percentage of intended dose taken) of 0.73 (0.55) for Ibuprofen, 0.76 (0.56) for diclofenac and 0.76 (0.55) for naproxen [19] .
No data were available regarding the use of over-the-counter medications which contain aspirin and NSAIDs, and this will have under-estimated exposure to these medicines. COX-2 inhibitors can only be obtained by prescription in the UK. However the reported prevalence of aspirin prescription is comparable with prevalence of selfreported aspirin use in other studies conducted in the UK [5] (22% in patients with UADT cancer and 26% in healthy participants). Immeasurable time bias [16] could also have affected the results as the included patients might have been hospitalised and received drugs without there being a record in the general medical practice.
However there was no data on hospitalisations available in the database.
Using 'ever' vs. 'never' categories for drug exposure also introduces immortal time bias [17] because it assumes that all participants had exposure to a drug from the start of follow-up. In observational studies some patients may not have survived to the day of their first prescription during follow-up, and may therefore have been classified as 'never users'. This could result in over-estimation of hazard ratios for 'ever' exposure to a drug. However unlike some treatments that may not be immediately available such as operations, aspirin (and some other NSAIDs) are easily available. In addition, we had prescription information both before and after diagnosis. In case of aspirin, the majority of patients (55% with HNC and 77% with oesophageal cancer) who were prescribed aspirin after diagnosis also had prescriptions before diagnosis. They were more likely to be continuous users and therefore exposed at baseline. To investigate this bias further, sensitivity analysis was conducted using nested case-control design to test the validity of the results [18] . This analysis showed moderate non-significant reduction in risk of death associated with aspirin prescription for both HNC and oesophageal cancer. To reduce immortal time bias, future larger studies should investigate the use Cox models with time-dependent exposures. Such models will need to assess the length of prescriptions and to clarify the longest acceptable gap between prescriptions that constitute 'continuous use'. Such a model would also facilitate the addressing of issues such as increased risks of bleeding (aspirin and NSAID users) and increased risks of cardiovascular events, a common cause of death (NSAID and COX2 users).
Hernández-Díaz and García Rodríguez [20] in the study of NSAIDs and risk of lung cancer performed a sensitivity analysis to quantify the impact of misclassification due to unrecorded over-the-counter use or to non-compliance. They concluded that the protective effect could not be explained by the unrecorded use. Yood et al [21] concluded from their sensitivity analysis that prescription data can give valid estimates of association even though some of the drugs are available over-the-counter.
We defined ever users as those with at least one prescription. Another study of prescriptions [22] similarly defined users as those with at least one prescription, while Friis et al [23] defined users as those with two or more prescriptions. Studies which collected information using questionnaires defined users as those who ever taken aspirin before the onset of illness [24] or as regular users (use at least once a week for a year) [5] .
While we adjusted for potential confounders such as deprivation, smoking and alcohol consumption, the quality of some of this information was poor. For example, there was a large amount of missing data for smoking (24%) and alcohol consumption (35%). We also used multiple imputation to replace the missing values for confounding factors.
In addition, we did not have information on other factors such history of HPV infection. It was shown that tumour HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer [25] .
There are risks associated with long term use of aspirin. A systematic review of observation studies of NSAIDs use showed an increased pooled Relative Risk of 3.8 (95% CI 3.6, 4.1) of upper gastrointestinal tract bleeding and perforation [26] .
However Rothwell et al [27] in the study of individual patient data from 51 randomised trials of short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death showed that the reduced risk of major vascular events was initially offset by an increased risk of major bleeding, but effects on both outcomes diminished with increasing follow-up, leaving only the reduced risk of cancer from 3 years onwards. Case-fatality from major extracranial bleeds was also lower on aspirin than on control (Odds Ratio (OR) 0·32, 95% CI 0·12, 0·83).
Population-based cross-sectional European Eye Study of participants 65 years of age and older, showed that frequent aspirin use was associated with early and late aging macula disorder (AMD), and the ORs rose with increasing frequency of consumption. For daily aspirin users, the ORs, showed an increase with increasing severity of AMD grades: grade 1, 1.26 (95% CI 1.08, 1.46); grade 2, 1.42 (95% CI 1.18, 1.70), and wet late AMD, 2.22 (95% CI, 1.61, 3.05) [28] .
Analysis of benefits and harms of prophylactic use of aspirin in the general population [29] suggested that in order to improve the benefit-harm ratio, future studies could identify individuals at high-risk of bleeding and either reduce their risk or not offer them prophylactic aspirin. Contraindications include peptic ulcer, recent bleeding episodes or bleeding tendencies. Other risk factors for bleeding in aspirin or NSAID users are increasing age, male sex, diabetes, hypertension, being overweight or obese, smoking, alcohol consumption and H. pylori infection [30] .
Conclusion
Aspirin and other NSAIDs prescriptions after diagnosis are associated with a reduced all-cause mortality in UADT cancer patients.These results should be replicated in other prescriptions databases using statistical models with timedependent exposures and different study designs. Further research is also needed to determine the optimum dose and duration of use, and to identify individuals at increased risk of bleeding before starting aspirin prophylaxis. # Among those surviving for more than 12 months ## Adjusted for age, gender, deprivation, year of diagnosis, smoking (ever), alcohol consumption (high), CHD, AF, Stroke, Aspirin ((before and after diagnosis ), COX-2 (before and after diagnosis), other NSAID (before and after diagnosis) and taking into account clustering within medical practices Prescription density was calculated as Number of prescriptions divided by follow up time 
